Evidence map›Paper›PMID 36789162›Full record

ArticleBio-protocol2023

Thrombopoietin-independent Megakaryocyte Differentiation of Hematopoietic Progenitor Cells from Patients with Myeloproliferative Neoplasms.

Chloe A L Thompson-Peach, Johannes Foßelteder, Andreas Reinisch, Daniel Thomas

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Chloe A L Thompson-PeachCancer Program, Precision Medicine Theme, South Australian Health, and Medical Research Institute (SAHMRI), University of Adelaide, Adelaide, SA, Australia.
Johannes FoßeltederDepartment of Internal Medicine, Division of Hematology, Medical University of Graz, Graz, Austria.
Andreas ReinischDepartment of Internal Medicine, Division of Hematology, Medical University of Graz, Graz, Austria.
Daniel ThomasCancer Program, Precision Medicine Theme, South Australian Health, and Medical Research Institute (SAHMRI), University of Adelaide, Adelaide, SA, Australia.
Medical University of Graz · ATUniversity of Adelaide · AU

Funding

Austrian Science Fund FWF I 5021Austrian Science Fund FWF P 32783
6 · The paper itself

Abstract

Primary hematopoietic stem and progenitor cell (HSPC)-derived megakaryocytes are a valuable tool for translational research interrogating disease pathogenesis and developing new therapeutic avenues for patients with hematologic disorders including myeloproliferative neoplasms (MPNs). Thrombopoietin (TPO)-independent proliferation and megakaryocyte differentiation play a central role in the pathogenesis of essential thrombocythemia and myelofibrosis, two MPN subtypes that are characterized by increased numbers of bone marrow megakaryocytes and somatic mutations in either

Indexed as

CollagenHematopoietic stem and progenitor cellsInterleukin-6Interleukin-9Megakaryocyte differentiationMyeloproliferative neoplasmThrombopoietinTPO-independent

Identifiers

PMID36789162
PMCPMC9901468
OpenAlexW4317425162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.